EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Translational Development Acquisition Corp. (TDAC) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Translational Development Acquisition Corp. $3.64, price $10.86, upside -66.5%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Financial Services · US · ISIN KYG9008W1050

TD Translational Development Acquisition Corp. logo Thin data Sep 23, 2026

Translational Development Acquisition Corp.

TDAC · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $3.64 · Strongly overvalued (−67%)
!Quality 29/100
!negative free cash flow
✓Ranks above peers (6/8)
!Narrow moat 19/100
!Evidence only low, so the estimate is less certain
Watch Translational Development Acquisition Corp. Ordinary Shares for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$10.90 $10.00 Fair Value $3.64 Feb 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

19‑month range $10.00 – $10.90 · fair‑value band $2.73 – $4.55 · the $10.86 price screens above the $3.64 fair value. Dashed = 300-day average. As of Sep 23, 2026.

Follow Translational Development Acquisition Corp. Ordinary Shares in your weekly email

Every Wednesday you see whether Translational Development Acquisition Corp. Ordinary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp.

Show more

Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.

Stock analysis

Translational Development Acquisition Corp. Ordinary Shares (TDAC) currently trades at $10.86, while our model-based Fair Value estimate is $3.64, implying the stock looks roughly 198.5% overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of $6.08 per share, and 0 of the 6 models we run sit above the $10.86 price.

Bear case: the Earnings-Based group reads lowest at $1.65, and 6 of the 6 models stay below the price. Evidence for this calculation is low.

Scenario range: $2.73 (bear) to $4.55 (bull), the price of $10.86 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Financial Services sector.

Translational Development Acquisition Corp. Ordinary Shares reported revenue of $0 in FY2025 versus $0 in FY2023. Reported net income was $6.4M in FY2025.

Key figures

Market cap $208M · P/E ratio 38.8 · EPS (TTM) $0.2800 · Return on assets (EBIT) −6,011% · EPS growth (YoY) −10.1% · Free cash flow −$608K · Net debt $170K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 26 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 5% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Financial Services peers we cover trades at −53% fair-value upside, at −67%, TDAC screens richer than that median.

Fair Value models

Bear $2.73 Fair Value $3.64 Bull $4.55
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.2056 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
P/E Multiple $3.21 $4.28 $5.35 63
Residual Income $6.00 $5.66 $4.33 61
P/B Multiple $4.20 $5.60 $7.00 55
All 6 models by family
Earnings-Based
Graham-Dodd $2.24 $5.96 $7.79 51
Lynch FV $1.15 $1.65 $2.14 48
Multiples
P/E Multiple $3.21 $4.28 $5.35 63
P/B Multiple $4.20 $5.60 $7.00 55
Asset-Based
NCAV (Graham) $4.53 $6.08 $9.07 51
Economic Profit
Residual Income $6.00 $5.66 $4.33 61

Open the full fair value analysis →

Notify me when TDAC reaches fair value

Put TDAC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 29/100

Of which business quality 34 · Market factors (momentum, volatility) 66

Profitability 21
Margins and returns on capital today
Quality Growth 68
Are margins and returns improving?
Fin. Strength 67
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 100
Calm price path (market factor)
Momentum 44
Price trend over the last 3–12 months (market factor)
52W Momentum 66
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

TDAC screens 199% overvalued. Compare with Lionheart III Corp →

Compare Translational Development Acquisition Corp. Ordinary Shares with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Shell Companies · 82 stocks

Beats the industry median on 5/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −67% · Below median
Profitability
Return on assets 0% · Above median
Operating margin (TTM) 0% · Top 25%
Growth and dividend
Revenue growth 0% · Top 25%

Valuation Multiplesvs Shell Companies median · lower = cheaper

P/E (TTM) 38.8× · Cheaper than median
P/B 1.19× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Shell Companies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Lionheart III Corp LION $11.36 $15.02 +32%
AA Mission Acquisition Corp AAM $0.0360 $0.0490 +36%
Berto Acquisition Corp TACO $10.46 $2.73 −74%
Metals Acquisition Corp MTAL $10.16 $20.32 +100%
Axiom Intelligence Acquisition Corp AXIN $10.33 $1.71 −83%
Bold Eagle Acquisition Corp BEAG $10.82 $4.00 −63%
Lionheart Holdings CUB $10.88 $5.06 −53%
Texas Ventures Acquisition III Corp TVACW $0.2210 $0.2600 +18%
TGE Value Creative Solutions Corp BEBE $10.04 $3.58 −64%
Leapfrog Acquisition Corporation LFAC $10.08 $4.10 −59%

Explore undervalued stocks

More undervalued Financial Services stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Translational Development Acquisition Corp. Ordinary Shares · Fair Value
$3.64 −199%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Translational Development Acquisition Corp. Ordinary Shares Fair Value". https://www.fairvalue-calculator.com/stock/TDAC

Frequently asked questions

Is Translational Development Acquisition Corp. (TDAC) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $3.64 versus a price of $10.86, about −67% upside (overvalued).
What is the fair value of TDAC?
Our model-based fair value for Translational Development Acquisition Corp. Ordinary Shares is $3.64 (as of Sep 23, 2026), built from audited fundamentals. The current price: $10.86.
What is the quality score of TDAC?
Translational Development Acquisition Corp. Ordinary Shares has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Translational Development Acquisition Corp. (TDAC)?
Our model-based price target is the fair value of $3.64 (as of Sep 23, 2026) from 6 valuation models. Cautious scenario $2.73, optimistic scenario $4.55. It is a calculation from audited fundamentals, not an analyst target.
What is the Translational Development Acquisition Corp. Ordinary Shares stock forecast for 2026?
Our models put fair value at $3.64, about −67% upside versus a price of $10.86 (overvalued). Cautious scenario $2.73, optimistic scenario $4.55. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Translational Development Acquisition Corp. (TDAC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Translational Development Acquisition Corp. Ordinary Shares it is $3.64 per share (as of Sep 23, 2026), against a price of $10.86. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is Translational Development Acquisition Corp. Ordinary Shares stock overvalued or undervalued in 2026?
As of Sep 23, 2026, TDAC trades above its calculated fair value: price $10.86, fair value $3.64, a gap of about −67% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TDAC?
No. The price is what the market pays today ($10.86); the fair value is what the company's own numbers justify ($3.64). For Translational Development Acquisition Corp. Ordinary Shares the two are $7.22 per share apart. That gap is exactly why we show both numbers side by side.
How much is Translational Development Acquisition Corp. Ordinary Shares worth?
The market values Translational Development Acquisition Corp. Ordinary Shares at about $208M (market capitalisation, as of Sep 23, 2026). Per share that is $10.86; our models calculate a fair value of $3.64 per share.
What do the bullish and bearish scenarios say about TDAC?
Our models span a range for Translational Development Acquisition Corp. Ordinary Shares: cautious scenario $2.73, base $3.64, optimistic $4.55 per share (as of Sep 23, 2026, price $10.86). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TDAC?
Translational Development Acquisition Corp. Ordinary Shares trades at a price-to-earnings ratio of 38.8 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $3.64 is built from several models across several years. Other multiples: P/B 1.2.
How far is TDAC from its 52-week high?
Translational Development Acquisition Corp. Ordinary Shares trades at $10.86, at its 52-week high of $10.90 and 5% above the low of $10.34 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $3.64 is for.
Which stocks are comparable to Translational Development Acquisition Corp. Ordinary Shares?
From the same area (Financial Services) we also value Lionheart III Corp, AA Mission Acquisition Corp, Berto Acquisition Corp, Metals Acquisition Corp, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Translational Development Acquisition Corp. Ordinary Shares stock attractive at the current price?
The data as of Sep 23, 2026: price $10.86, calculated fair value $3.64 (−67%), Quality Score 29/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TDAC calculated?
We run Translational Development Acquisition Corp. Ordinary Shares through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.64, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Translational Development Acquisition Corp. Ordinary Shares itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Translational Development Acquisition Corp. (TDAC)?
The closing price on Sep 24, 2026 was $10.86. Our model-based fair value is $3.64, about −67% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Translational Development Acquisition Corp. Ordinary Shares right now?
The price sits above even our optimistic bull case ($4.55). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.

Key figures of Translational Development Acquisition Corp. Ordinary Shares

How large is the market capitalisation of Translational Development Acquisition Corp. (TDAC)?
The market capitalisation of Translational Development Acquisition Corp. Ordinary Shares is $208M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Translational Development Acquisition Corp. (TDAC)?
Earnings per share at Translational Development Acquisition Corp. Ordinary Shares are $0.2800 (price ÷ EPS = P/E 38.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Translational Development Acquisition Corp. (TDAC)?
On an EBIT basis the return on assets of Translational Development Acquisition Corp. Ordinary Shares is −6,011% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast are earnings growing at Translational Development Acquisition Corp. (TDAC)?
Earnings per share at Translational Development Acquisition Corp. Ordinary Shares are growing −10.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Translational Development Acquisition Corp. (TDAC) generate?
The free cash flow of Translational Development Acquisition Corp. Ordinary Shares is −$608K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Translational Development Acquisition Corp. (TDAC) carry?
The net debt of Translational Development Acquisition Corp. Ordinary Shares is $170K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Translational Development Acquisition Corp. Ordinary Shares in the live analysis

One click puts Translational Development Acquisition Corp. Ordinary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.